Approved Risk Evaluation and Mitigation Strategies (REMS)

Contact Us | REMS Basics | Gov Delivery Get REMS Email Alerts | Reports & Data Files

Caprelsa (vandetanib)
NDA #022405
REMS last update: 05/16/2017



What is the purpose of the REMS?

The goals of the CAPRELSA REMS Program are to mitigate the serious risks of QT prolongation, Torsades de pointes, and sudden death associated with use of CAPRELSA by:

  1. Educating prescribers on the following:
    1. Serious risks of QT prolongation, Torsades de pointes, and sudden death associated with use of CAPRELSA.
    2. The need to monitor for QT prolongation and electrolyte abnormalities.
    3. Appropriate management of QT prolongation to minimize the occurrence of Torsades de pointes and sudden death associated with use of CAPRELSA.
  2. Informing patients on the following:
    1. Serious risks of QT prolongation, Torsades de pointes, and sudden death associated with use of CAPRELSA.

What do participants need to know?

Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.

View application holder(s) REMS Website See Disclaimer page regarding links to external sites

Health Care Providers who prescribe Caprelsa must

To become certified to prescribe
Before treatment initiation
  • Counsel the patient or caregiver using the Patient Brochure.
    | Patient Brochure |

Patients who are prescribed Caprelsa

Before the first prescription
  • Receive counseling from the prescriber using the Patient Brochure.
    | Patient Brochure |

Pharmacies that dispense Caprelsa must

To become certified to dispense
  • Train all relevant staff involved in dispensing on the REMS program requirements.
  • Establish processes and procedures to verify prescriber enrollment.
  • Designate an authorized representative to carry out the certification process on behalf of the pharmacy.
  • Have the authorized representative enroll in the REMS Program by completing the Pharmacy Enrollment Form.
    | Pharmacy Enrollment Form |
Before dispensing
  • Verify that the prescriber is enrolled through the processes and procedures established as a requirement of the REMS Program.
At all times
  • Maintain records of prescriber certification each time the drug is dispensed.

Wholesalers that distribute Caprelsa must

To be able to distribute
  • Establish processes and procedures to ensure that the drug is distributed only to certified pharmacies.
At all times
  • Comply with audits carried out by the REMS Program to ensure that all processes and procedures are in place and are being followed.

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers. For a specific Medication Guide of a product in the Caprelsa REMS, see the DailyMed link(s).
Material Name Material Name Link
Patient Brochure (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Caprelsa_2017-05-16_Patient_Brochure.pdf
Pharmacy Enrollment Form (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Caprelsa_2017-05-16_Pharmacy_Enrollment_Form.pdf
Prescriber Enrollment Form Screenshots (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Caprelsa_2017-05-16_Prescriber_Enrollment_Form_Screenshots.pdf
Prescriber Training Pamphlet (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Caprelsa_2017-05-16_Prescriber_Training_Pamphlet.pdf
Prescriber Training Questions (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Caprelsa_2017-05-16_Prescriber_Training_Questions.pdf
Prescriber Training Slide Deck (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Caprelsa_2017-05-16_Prescriber_Training_Slide_Deck.pdf
REMS Document (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Caprelsa_2017-05-16_REMS_Document.pdf
REMS Full (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Caprelsa_2017-05-16_Full.pdf
REMS Website Screenshots (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Caprelsa_2017-05-16_REMS_Website_Screenshots.pdf

What updates have been made to the REMS?

Date Summary of change
05/16/2017 Modified to:

  1. Remove the Medication Guide and the communication plan.
  2. Add the Caprelsa REMS Patient Brochure.
  3. Add changes to the REMS Document including updates to the goals and change in ownership.
  4. Include minor clarifying edits to the following REMS materials to accurately explain the enrollment process and prioritize the presentation of risk information: Caprelsa REMS Prescriber Training Slide Deck, Prescriber Training Pamphlet, Prescriber Training Questions, REMS website screen shots, and Pharmacy Enrollment Form.
11/27/2013 Modified to add information about the risk of upper respiratory tract infection to the Medication Guide.
06/22/2011 Modified to:

  1. Add the CAPRELSA (vandetanib) name to the Medication Guide and other REMS materials.
  2. Make editorial changes requested by FDA.
04/06/2011 Approval of the REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English